Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study

Phase 2

Completed

Conditions: HIV Infections

First Posted Date: 2006-01-12

Last Posted Date: 2023-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 216

Registration Number: NCT00275444

Locations: 🇺🇸
Mercer University School of Medicine, Macon, Georgia, United States
🇺🇸
John's Hopkins University, Baltimore, Maryland, United States
🇺🇸
Rush-Presbytarian-St Luke's Medical Center, Chicago, Illinois, United States

and more 41 locations

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2006-01-11

Last Posted Date: 2013-12-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 805

Registration Number: NCT00274638

Locations: 🇺🇸
Herron Medical Center, Ltd., Chicago, Illinois, United States
🇺🇸
Midwest Institute for Clinical Research Inc., Indianapolis, Indiana, United States
🇺🇸
nTouch Research, Houston, Texas, United States

and more 50 locations

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2006-01-11

Last Posted Date: 2023-12-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 812

Registration Number: NCT00274599

Locations: 🇺🇸
Spartanburg Medical Research, Spartanburg, South Carolina, United States
🇺🇸
Harold B. Betton, M.D., Little Rock, Arkansas, United States
🇺🇸
GFI Pharmaceuticals, Evansville, Indiana, United States

and more 7 locations

Effect of Tiotropium (Spiriva) on Exercise Tolerance in COPD Patients

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-01-11

Last Posted Date: 2023-12-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 261

Registration Number: NCT00274508

Locations: 🇺🇸
St. Thomas Health Services, Nashville, Tennessee, United States
🇺🇸
Presbyterian Hospital of Dallas, Dallas, Texas, United States
🇨🇦
Department of Respiratory Medicine, Toronto, Ontario, Canada

and more 21 locations

A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-01-11

Last Posted Date: 2013-11-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT00274534

Locations: 🇺🇸
Hunter Holmes McGuire Medical Center, Richmond, Virginia, United States
🇺🇸
Hines Veterans Administration Hospital, Hines, Illinois, United States

Tiotropium (Spiriva) Rehabilitation Study

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-01-11

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 108

Registration Number: NCT00274521

Locations: 🇺🇸
Harbor-UCLA Research and Education Institute, Torrance, California, United States
🇺🇸
St. Francis Hospital and Medical Center, Hartford, Connecticut, United States
🇺🇸
Temple University Hospital, Philadelphia, Pennsylvania, United States

and more 9 locations

Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM

Phase 4

Completed

Conditions: Hypertension

First Posted Date: 2006-01-11

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 801

Registration Number: NCT00274612

Locations: 🇦🇹
Rehabilitationszentrum für Herz- und Kreislauferkrankungen, Bad Tatzmannsdorf, Austria
🇦🇹
Landeskrankenhaus Graz West, Graz, Austria
🇦🇹
Univ.-Klinik für Innere Medizin III, Wien, Austria

and more 16 locations

Tiotropium (18 Mcg) Once Daily Via the HandiHaler® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-01-11

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1829

Registration Number: NCT00274547

Locations: 🇺🇸
Boehringer Ingelheim Investigational Site, Salt Lake City, Utah, United States
🇺🇸
Hampton VA Medical Center, Hampton, Virginia, United States
🇺🇸
Carl T. Hayden VA Medical Center, Phoenix, Arizona, United States

and more 10 locations

Headache Study to Compare Aggrenox Full Dose and Reduced Dose

Phase 3

Completed

Conditions: Cerebrovascular Accident

First Posted Date: 2006-01-11

Last Posted Date: 2013-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 100

Registration Number: NCT00274586

Locations: 🇨🇳
Chang Gung Memorial Hospital, Taipei, Taiwan

Effects of Once Daily Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2006-01-11

Last Posted Date: 2013-11-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1639

Registration Number: NCT00274573

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Zwickau, Germany
🇩🇪
MEDARS GmbH, Berlin, Germany
🇩🇪
Johannes-Gutenberg-Universität Mainz, Mainz, Germany

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy